Literature DB >> 11454700

Identification of fibroblast growth factor-5 as an overexpressed antigen in multiple human adenocarcinomas.

K Hanada 1, D M Perry-Lalley, G A Ohnmacht, M P Bettinotti, J C Yang.   

Abstract

Methodology for identifying tumor-associated antigens recognized by T cells has been successfully used to clone antigens from melanoma cells. Similar efforts for nonmelanoma tumors have had limited success with few antigens identified. To identify potentially relevant tumor-associated antigens expressed in renal cell carcinoma cell lines, a tumor-specific CTL clone was established from tumor-infiltrating lymphocytes from a regressing pulmonary lesion. This CTL recognized nonmutated fibroblast growth factor-5 (FGF-5). Quantitative real-time reverse transcription PCR revealed that FGF-5 was overexpressed in the majority of renal cell carcinomas, as well as in some prostate carcinoma and breast carcinoma lines. FGF-5 expression by quantitative real-time reverse transcription PCR in normal tissues was below the recognition threshold for this CTL. As a normal protein with significant overexpression by multiple adenocarcinomas and little normal tissue expression, FGF-5 represents an immunotherapy target with potential utility against a broad array of nonmelanoma cancers.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11454700

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  18 in total

Review 1.  Novel biochemistry: post-translational protein splicing and other lessons from the school of antigen processing.

Authors:  Ken-ichi Hanada; James C Yang
Journal:  J Mol Med (Berl)       Date:  2005-03-10       Impact factor: 4.599

2.  Inducement of specific CTLs by antigen-peptides from human leukemia cells and their cytotoxicity to leukemia cells.

Authors:  Zuohua Feng; Guimei Zhang; Bo Huang; Dong Li; Hongtao Wang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2002

3.  Mobilization of dendritic cell precursors in patients with cancer by flt3 ligand allows the generation of higher yields of cultured dendritic cells.

Authors:  Carlos E Marroquin; Jennifer A Westwood; Rejean Lapointe; Arnold Mixon; John R Wunderlich; Dania Caron; Steven A Rosenberg; Patrick Hwu
Journal:  J Immunother       Date:  2002 May-Jun       Impact factor: 4.456

4.  Development of a genetically-modified novel T-cell receptor for adoptive cell transfer against renal cell carcinoma.

Authors:  Qiong J Wang; Ken-ichi Hanada; Steven A Feldman; Yangbing Zhao; Takashi Inozume; James C Yang
Journal:  J Immunol Methods       Date:  2011-01-19       Impact factor: 2.303

5.  Distinctive features of the differentiated phenotype and infiltration of tumor-reactive lymphocytes in clear cell renal cell carcinoma.

Authors:  Qiong J Wang; Ken-Ichi Hanada; Paul F Robbins; Yong F Li; James C Yang
Journal:  Cancer Res       Date:  2012-10-15       Impact factor: 12.701

6.  Regression of human kidney cancer following allogeneic stem cell transplantation is associated with recognition of an HERV-E antigen by T cells.

Authors:  Yoshiyuki Takahashi; Nanae Harashima; Sachiko Kajigaya; Hisayuki Yokoyama; Elena Cherkasova; J Philip McCoy; Ken-Ichi Hanada; Othon Mena; Roger Kurlander; Abdul Tawab; Tawab Abdul; Ramaprasad Srinivasan; Andreas Lundqvist; Elizabeth Malinzak; Nancy Geller; Michael I Lerman; Richard W Childs
Journal:  J Clin Invest       Date:  2008-03       Impact factor: 14.808

7.  A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer.

Authors:  James C Yang; Leah Haworth; Richard M Sherry; Patrick Hwu; Douglas J Schwartzentruber; Suzanne L Topalian; Seth M Steinberg; Helen X Chen; Steven A Rosenberg
Journal:  N Engl J Med       Date:  2003-07-31       Impact factor: 91.245

8.  Relationship of p53 overexpression on cancers and recognition by anti-p53 T cell receptor-transduced T cells.

Authors:  Marc R Theoret; Cyrille J Cohen; Azam V Nahvi; Lien T Ngo; Kimberly B Suri; Daniel J Powell; Mark E Dudley; Richard A Morgan; Steven A Rosenberg
Journal:  Hum Gene Ther       Date:  2008-11       Impact factor: 5.695

9.  FGF5 as an oncogenic factor in human glioblastoma multiforme: autocrine and paracrine activities.

Authors:  S Allerstorfer; G Sonvilla; H Fischer; S Spiegl-Kreinecker; C Gauglhofer; U Setinek; T Czech; C Marosi; J Buchroithner; J Pichler; R Silye; T Mohr; K Holzmann; B Grasl-Kraupp; B Marian; M Grusch; J Fischer; M Micksche; W Berger
Journal:  Oncogene       Date:  2008-03-24       Impact factor: 9.867

10.  T cells associated with tumor regression recognize frameshifted products of the CDKN2A tumor suppressor gene locus and a mutated HLA class I gene product.

Authors:  Jianping Huang; Mona El-Gamil; Mark E Dudley; Yong F Li; Steven A Rosenberg; Paul F Robbins
Journal:  J Immunol       Date:  2004-05-15       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.